The Management of Prostatic Obstruction: How to Determine the Best Options?  C.G Roehrborn, T McNicholas  European Urology Supplements  Volume 2, Issue 8, Pages 13-19 (November 2003) DOI: 10.1016/j.eursup.2003.09.010

Fig. 1 Cumulative treatment discontinuation rates in men with benign prostatic hyperplasia in individual studies [2]. European Urology Supplements 2003 2, 13-19DOI: (10.1016/j.eursup.2003.09.010)

Fig. 2 Greater suppression of dihydrotestosterone (DHT) levels achieved with dutasteride (Dut) versus finasteride (Fin). European Urology Supplements 2003 2, 13-19DOI: (10.1016/j.eursup.2003.09.010)

Fig. 3 Pooled adjusted mean change from baseline in American Urological Symptom Index (AUA-SI) with dutasteride and placebo. Reproduced with permission Roehrborn CG et al. Urology 2002;60:434–441. European Urology Supplements 2003 2, 13-19DOI: (10.1016/j.eursup.2003.09.010)

Fig. 4 Pooled adjusted mean change from baseline in prostate volume with dutasteride and placebo. European Urology Supplements 2003 2, 13-19DOI: (10.1016/j.eursup.2003.09.010)

Fig. 5 Pooled data for the first episode of acute urinary retention (AUR). Reproduced with permission Roehrborn CG et al. Urology 2002;60:434–441. European Urology Supplements 2003 2, 13-19DOI: (10.1016/j.eursup.2003.09.010)